2023
Pharmacologic Management of Autosomal Dominant Polycystic Kidney Disease
Ackley W, Dahl N, Park M. Pharmacologic Management of Autosomal Dominant Polycystic Kidney Disease. Advances In Kidney Disease And Health 2023, 30: 228-235. PMID: 37088525, DOI: 10.1053/j.akdh.2023.02.002.Peer-Reviewed Original ResearchConceptsAutosomal dominant polycystic kidney diseaseEnd-stage kidney diseaseKidney diseaseDominant polycystic kidney diseasePolycystic kidney diseaseRapid progressionMechanism-specific treatmentsChronic kidney diseaseFourth leading causeTreatment of patientsPharmacologic managementLeading causeKidney disordersFDA approvalDiseaseTolvaptanProgressionTreatmentRiskMorbidityPatientsPathogenesisTherapy
2018
A Practical Guide for Treatment of Rapidly Progressive ADPKD with Tolvaptan
Chebib FT, Perrone RD, Chapman AB, Dahl NK, Harris PC, Mrug M, Mustafa RA, Rastogi A, Watnick T, Yu ASL, Torres VE. A Practical Guide for Treatment of Rapidly Progressive ADPKD with Tolvaptan. Journal Of The American Society Of Nephrology 2018, 29: 2458-2470. PMID: 30228150, PMCID: PMC6171265, DOI: 10.1681/asn.2018060590.Peer-Reviewed Original ResearchConceptsAutosomal dominant polycystic kidney diseaseOpen-label extension studyProgressive autosomal dominant polycystic kidney diseaseFirst drug treatmentRenal protective measuresKidney function declineLiver enzyme elevationCare of patientsConfirmation of diagnosisEducation of patientsCounseling of patientsDominant polycystic kidney diseasePolycystic kidney diseaseTolvaptan treatmentProgressive diseaseEnzyme elevationFunction declineKidney diseaseClinical trialsGeneral practitionersDrug treatmentTreatment efficacyPatientsTolvaptanUS Food